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Objectives:  Human  epidermal  growth  factor  receptor  3 (HER3)  is  a key  dimerization  partner  for  HER
family  members  and  is associated  with  resistance  to  other  HER  family  receptor-targeted  therapeutics.
This  study  evaluated  the safety,  tolerability,  pharmacokinetics  and  efﬁcacy  of patritumab  (U3-1287),  a
fully human  anti-HER3  monoclonal  antibody,  in combination  with  erlotinib,  an  epidermal  growth  factor
receptor-tyrosine  kinase  inhibitor  in  patients  with  previously  treated  advanced  non-small  cell lung  cancer
(NSCLC).
Patients and  methods:  This  study  enrolled  patients  with  stage  IIIB/IV  NSCLC  with  Eastern  Cooperative
Oncology  Group  performance  status  0–1, life  expectancy  >3 months  and  who  had  progressed  after  at
least  one  prior  course  of  chemotherapy  (excluding  erlotinib).  This  open-label  study  included  two  parts:
dose  escalation  (Part  1)  and  dose  expansion  (Part  2).  In  Part  1, patients  received  intravenous  patritumab  9
or 18 mg/kg  every  3  weeks  in  addition  to  per-oral  erlotinib  150 mg/day  daily.  In Part  2,  patients  received
the  recommended  dose  of patritumab  as  determined  in Part  1. Adverse  event  rates,  pharmacokinetics
and  tumor  responses  were determined.
Results:  Twenty-four  Japanese  patients  received  patritumab  at 9 mg/kg  (n = 3)  or 18 mg/kg  (n =  21),  and
erlotinib.  No  dose-limiting  toxicities  were  reported,  indicating  the  maximum-tolerated  dose  was  not
reached.  The  most  frequent  adverse  events  were  gastrointestinal  or skin  toxicities,  which  were  generally
mild  and manageable.  Patritumab  pharmacokinetics  were  similar  to those  reported  in previous  studies.
The median  progression-free  survival  (95%  conﬁdence  interval)  was  44.0  (22.0–133.0)  days  for  the EGFR
wild-type  group  (n = 9)  and 107.0  (74.0–224.0)  days  for the  EGFR-activating  mutation  group  (n =  13).  Eval-
uation  of biomarkers  by  immunohistochemical  analysis  did not  indicate  a  relationship  between  efﬁcacy
and  HER3  expression  in tumor
Conclusion:  Patritumab  in  com
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. Introduction
The human epidermal growth factor receptor (HER) family con-
ists of four structurally related cellular receptors (Her1, Her2, Her3,
er4) that are expressed on the surface of cells and contain extra-
ellular, transmembrane, and tyrosine kinase domains. Each of
hese domains is responsible for a different aspect of HER signaling
athways. Ligand binding to HERs results in the formation of homo-
r heterodimers that activate receptor tyrosine kinases and subse-
uently downstream PI3K and AKT pathway signaling to mediate
arious cellular processes including morphogenesis, proliferation,
ngiogenesis, and survival [1]. Thus, inappropriate activation of
ER signaling pathways might cause the growth and spread of
ancer cells.
HER3 is the only HER family member that lacks tyrosine kinase
ctivity because of an amino acid substitution in the conserved
inase domain. Thus, interactions of HER3 with binding partners
re essential for its biological activity [2]. In particular, HER3
otently activates downstream PI3K and AKT pathway signaling
y directly binding to PI3K through six consensus phosphotyrosine
ites [3]. HER3 is overexpressed in various solid tumors including
on-small cell lung cancer (NSCLC) [4–7], and is a poor prognostic
actor as patients with these cancers have shorter survival [8–11].
n vitro studies have conﬁrmed the direct involvement of HER3 in
ancer cell growth [12–14]. Moreover, a recent study suggested
hat HER3 was involved in the development of resistance to other
ER family receptor(s)-targeted therapeutics [12]. Therefore, HER3
s considered an important target for cancer chemotherapy.
Patritumab is a fully human monoclonal immunoglobulin G1
IgG1) antibody [15] that speciﬁcally binds to the extracellular
omains of HER3, thereby inhibiting downstream signal trans-
uction and reducing HER3 expression [15]. A more recent study
ndicated that patritumab abrogated cetuximab resistance in colo-
ectal cancer cells by inhibiting the phosphorylation of EGFR, HER2,
ER3, ERK, and AKT [16]. In a mouse model of human NSCLC using
 Calu-3 (a cell line) xenograft, administration of patritumab alone
nhibited tumor proliferation. In addition, the combined use of
atritumab with erlotinib, an epidermal growth factor receptor-
yrosine kinase inhibitor (EGFR-TKI), led to increased inhibition of
umor proliferation, compared with patritumab alone [17].
In a phase I study (ClinicalTrials.gov Identiﬁer: NCT00730470),
he tolerability and safety of patritumab in patients with advanced
olid tumors were evaluated. No dose-limiting toxicity (DLT) was
bserved at doses of 0.3–20 mg/kg, the maximum tolerated dose
MTD) was not reached, and the safety of doses up to 20 mg/kg was
onﬁrmed [18]. In another phase I study (ClinicalTrials.jp Identiﬁer:
apicCTI-101262), the tolerability and safety of patritumab at doses
f 9 mg/kg and 18 mg/kg were evaluated in Japanese patients with
dvanced solid tumors. No DLTs were observed at the dose levels
tudied and the MTD  was not reached [19].
Based on an in vivo study showing that combined patritumab
nd erlotinib enhanced inhibition of tumor proliferation, compared
ith patritumab alone [20], the current study evaluated the safety
nd pharmacokinetics of patritumab combined with erlotinib and
etermined the recommended dose for subsequent clinical studies.
nti-patritumab antibody formation, tumor responses and poten-
ial biomarkers related to patritumab were also evaluated.
. Patients and methods
.1. PatientsThis study enrolled stage IIIB/IV NSCLC patients who had pro-
ressed after at least one prior course of chemotherapy. Patients
ere 20–75 years old at the time of provision of informed consent,r 88 (2015) 275–281
had measurable disease as per the response evaluation crite-
ria in solid tumors (RECIST v.1.1, Japanese version) [21], had an
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) of 0–1 [22], and a life expectancy of more than 3 months.
Additional inclusion criteria required for patients were adequate
hematologic, hepatic and renal function. Eligible patients must
have recovered from any toxicity related to prior therapy, except
for alopecia. Exclusion criteria included a history of erlotinib or
anti-HER3 therapy (prior geﬁtinib therapy allowed); other active
malignancies; history or presence of interstitial lung disease; his-
tory (within 6 months before enrollment) or presence of severe
cardiovascular or cerebrovascular disease, pulmonary thrombosis,
deep vein thrombosis, or other clinically severe pulmonary dis-
ease; any of the following complications including clinically severe
infections requiring systemic administration of an antimicrobial
agent, antiviral agent or other agents; presence of chronic diarrhea,
inﬂammatory bowel disease or partial ileus; presence of peptic
ulcer; ﬂuid retention requiring treatment; corneal disease; uncon-
trolled diabetes mellitus; hypertension; psychiatric symptoms; a
positive test for hepatitis B virus surface antigen, hepatitis C virus
antibody or human immunodeﬁciency virus antibody; history of a
bleeding diathesis; and history of serious hypersensitivity to drugs
containing polysorbate 20.
The study protocol was approved by each participating Institu-
tional Review Board and each patient provided written informed
consent.
2.2. Study design
This was a multicenter open-label trial conducted in two parts:
dose escalation (Part 1) and dose expansion (Part 2). In Part 1,
evaluation of the DLT for the combined treatment with patri-
tumab and erlotinib was conducted at two  dose levels: 9 mg/kg and
18 mg/kg patritumab where dose escalation followed a modiﬁed
3 + 3 design. The recommended dose of 18 mg/kg patritumab alone
was previously determined in a phase I study [19]. Patients were
initially enrolled in a cohort to receive patritumab 9 mg/kg (Level 1)
every 3 weeks in combination with an oral daily dose of erlotinib
150 mg.  Patritumab was administered as an intravenous infusion
over 60 minutes. The ﬁrst cycle (Day 1–21, with Day 1 deﬁned as
the ﬁrst day of patritumab administration) served as the DLT eval-
uation period. If DLTs were observed in less than 33% of patients,
the dose was escalated to 18 mg/kg (Level 2).
DLTs were deﬁned as toxicities graded in accordance with
the National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE v4.0) [21] and assessed as related to either
patritumab or erlotinib: (1) grade 3 or higher febrile neutropenia,
or persistent (7 days or longer) grade 4 neutropenia, (2) grade 4
thrombocytopenia, or grade 3 thrombocytopenia requiring blood
transfusion, (3) uncontrollable grade 3 or higher fatigue, anorexia,
nausea, vomiting, skin disorder (e.g., skin eruption, urticaria), and
diarrhea despite maximal supportive therapy, (4) grade 3 or higher
toxicity, with the exception of (1)–(3) as well as pyrexia without
neutropenia, transient electrolyte abnormality, and transient lab-
oratory abnormality not requiring treatment and without clinical
symptoms, and (5) toxicity requiring suspension of erlotinib ther-
apy for more than 7 days during the DLT evaluation period. The MTD
was deﬁned as the highest dose level in the ﬁrst cycle at which the
frequency of DLT was below 33%.
Part 2 was designed to assess further the safety of the com-
bined treatment in 18 patients using the recommended dose that
was determined in Part 1. The target sample size for the U3-
1287 + erlotinib combination therapy arm in the phase II study
(ClinicalTrials.gov Identiﬁer: NCT01211483) was 130 subjects. We
selected 21 patients for the phase II study (3 for Part 1 and 18 for Part
2) based on that being approximately 15% of the target sample size.
 Cancer 88 (2015) 275–281 277
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Table 1
Demographics and baseline characteristics.
Patritumab 9 mg/kg Patritumab 18 mg/kg Overall
N = 3 (%) N = 21 (%) N = 24 (%)
Sex
Male 3 (100) 13 (61.9) 16 (66.7)
Female 0 8 (38.1) 8 (33.3)
Age (years)
Median (range) 60.0 (53–69) 67.0 (36–73) 66.5 (36–73)
ECOG PSa
0 2 (66.7) 7 (33.3) 9 (37.5)
1  1 (33.3) 14 (66.7) 15 (62.5)
Histology
Adenocarcinoma 2 (66.7) 17 (81.0) 19 (79.2)
Squamous cell 0 3 (14.3) 3 (12.5)
Large cell 0 1 (4.8) 1 (4.2)
Other 1 (33.3) 0 1 (4.2)
Stage
IIIB  0 0 0
IV  3 (100) 21 (100) 24 (100)
EGFR genotype
Wild-type 1 (33.3) 8 (38.1) 9 (37.5)
Mutations 1 (33.3) 12 (57.1) 13b (54.2)
Exon 19 1 (33.3) 6 (28.6) 7 (29.2)
L858R 0 5 (23.8) 5 (20.8)
Exon 18 and 21 0 1 (4.8) 1 (4.2)
T790M 0 0 0
Unknown 1 (33.3) 1 (4.8) 2 (8.3)
Number of prior chemotherapy lines
Median (range) 4.0 (2–4) 2.0 (1–4) 2.5 (1–4)M. Nishio et al. / Lung
n addition, the incidences of anti-patritumab antibodies, tumor
esponse and related biomarkers were assessed.
.3. Safety evaluation
Adverse events (AEs) were evaluated according to CTCAE v4.0
hroughout the treatment period until 30 days after administration
f the last dose (patritumab or erlotinib). Safety evaluations were
ased on a medical review of AEs and the results of clinical labo-
atory tests, vital sign measurements, 12-lead electrocardiograms,
hysical examination, ECOG PS, and X-ray/computed tomography
cans. The presence of anti-patritumab antibodies was assessed
efore each treatment cycle and measured by electrochemilumi-
escence immunoassay.
.4. Pharmacokinetics
Pharmacokinetics were evaluated in 3 patients in the 9 mg/kg
ose group and in 11 patients in the 18 mg/kg dose group. Blood
amples were collected at pre-dose and 1 (end of infusion), 4, 7,
4 and 72 h after the start of ﬁrst dose infusion, on Days 8 and 15
f Cycle 1, and on Day 1 of Cycles 2, 3 and 4. Serum patritumab
oncentrations were measured by enzyme-linked immunosorbent
ssay (ELISA). Pharmacokinetic parameters after the ﬁrst dose were
alculated by non-compartmental analysis using WinNonlin (Ver
.2.1, Pharsight Corp., CA, USA). Pharmacokinetic statistical anal-
ses were performed using SAS System Release 9.2 (SAS Institute
apan Ltd., Tokyo, Japan).
.5. Tumor response
Tumor responses were evaluated using RECIST v 1.1, Japanese
ersion [22]. Disease responses were assessed at screening and at
he end of Cycle 2 and every 6 weeks thereafter.
.6. Biomarkers
Analysis of biomarkers using tumor tissues was  performed
nly for patients who had provided written informed consent to
articipate in biomarker research. Parafﬁn-embedded samples of
rchived tumor tissues were used to evaluate HER3 protein expres-
ion level by immunohistochemistry. The frequency of HER3 gene
mpliﬁcation was assessed by ﬂuorescence in situ hybridization at
osaic Laboratories (Lake Forest, CA, USA).
Serum HER3 levels were also evaluated in all patients. Blood
or serum biomarkers was collected on Day 1 (before administra-
ion), 8, 15 and 21 of Cycle 1, and Day 21 of Cycle 2 and every 6
eeks thereafter, and changes in soluble HER3 serum levels were
valuated. Soluble HER3 levels were measured by ELISA.
.7. Statistical methods
All patients who received study medication were included in
he analysis of safety and efﬁcacy. Safety and efﬁcacy data were
ummarized as descriptive statistics using SAS System Release 8.2
SAS Institute Japan Ltd., Tokyo, Japan). In this study, no signiﬁcance
evel was established because no hypothesis test was  performed.
. Results
.1. Patient characteristicsOf the 25 patients enrolled in this study, 1 was  ineligible because
f suspected radiation pneumonitis after registration and with-
rew before receiving any study treatment. Therefore, the study
rug was administered to 24 patients. In Part 1, 3 patients receiveda Eastern Cooperative Oncology Group performance status.
b 12 of 13 patients received prior geﬁtinib therapy.
EGFR, epidermal growth factor.
patritumab 9 mg/kg (Level 1) and 3 patients received patritumab
18 mg/kg (Level 2); in Part 2, 18 patients received patritumab
18 mg/kg.
Patient characteristics are summarized in Table 1. Eight patients
were female and 16 patients were male. The median age (range)
was 66.5 (36–73) years. Tumor genotyping of EGFR showed wild-
type EGFR in 9 patients (37.5%), deletion of exon 19 (Exon 19 del) in 7
patients (29.2%), substitution of amino acid arginine with leucine at
858 (L858R) in 5 patients (20.8%), deletion of exon 18 and 21 (exon
18 and 21 del) in 1 patient (4.2%), and was  unknown in 2 patients
(8.3%). The median (range) number of lines of prior chemotherapy
was 2.5 (1–4).
3.2. Safety
Throughout the study, adverse events (AEs) were reported in all
24 patients as summarized in Table 2. The most common over-
all AEs (≥50%) were diarrhea, stomatitis, paronychia, dermatitis
acneiform, dry skin, decreased weight, and decreased appetite,
which were generally mild and manageable. Most of the AEs were
related to both patritumab and erlotinib, and were generally mild
and manageable. No grade 5 AEs were reported. One patient receiv-
ing patritumab 18 mg/kg had a decreased lymphocyte count, which
was a grade 4 AE. Serious adverse events (SAEs) including bacterial
pneumonia, abnormal hepatic function, bacterial infection, cancer
pain, and acneiform rash were reported in 4 patients, and these
events required hospitalization. No DLT was reported during the
DLT observation window and the tested doses did not reach the
MTD. No patients developed anti-patritumab antibodies after the
administration of patritumab in this study.
3.3. PharmacokineticsSerum patritumab pharmacokinetic parameters are summa-
rized in Table 3. For the 9 and 18 mg/kg dose groups, the mean area
under the curve (AUC) values were 1190 and 2480 g/day/mL; the
278 M. Nishio et al. / Lung Cancer 88 (2015) 275–281
Table 2
Treatment-emergent adverse events in more than 10% of patients.
Preferred term Patritumab 9 mg/kg (N = 3) Patritumab 18 mg/kg (N = 21) Overall (N = 24)
≥3 Any grades ≥3 Any grades Any grades
N  N (%) N N (%) N (%)
Diarrhea 0 3 (100.0) 4 20 (95.2) 23 (95.8)
Stomatitis 0 2 (66.7) 1 20 (95.2) 22 (91.7)
Paronychia 0 2 (66.7) 1 18 (85.7) 20 (83.3)
Dermatitis acneiform 0 2 (66.7) 3 15 (71.4) 17 (70.8)
Dry  skin 0 2 (66.7) 0 13 (61.9) 15 (62.5)
Weight  decreased 0 3 (100.0) 0 10 (47.6) 13 (54.2)
Decreased appetite 0 3 (100.0) 0 9 (42.9) 12 (50.0)
Rash  maculo-papular 0 3 (100.0) 1 8 (38.1) 11 (45.8)
Nausea  0 2 (66.7) 0 8 (38.1) 10 (41.7)
Dysgeusia 0 1 (33.3) 0 8 (38.1) 9 (37.5)
Cheilitis 0 0 (0.0) 0 7 (33.3) 7 (29.2)
Vomiting 0 2 (66.7) 0 5 (23.8) 7 (29.2)
Malaise 0 3 (100.0) 0 4 (19.0) 7 (29.2)
Blood  bilirubin increased 1 1 (33.3) 0 6 (28.6) 7 (29.2)
Alanine  aminotransferase increased 0 0 (0.0) 1 6 (28.6) 6 (25.0)
Hypoalbuminemia 0 0 (0.0) 0 5 (23.8) 5 (20.8)
Pruritus 0 0 (0.0) 0 5 (23.8) 5 (20.8)
Fatigue 0 0 (0.0) 0 5 (23.8) 5 (20.8)
Aspartate aminotransferase increased 0 0 (0.0) 0 5 (23.8) 5 (20.8)
Lymphocyte count decreased 0 0 (0.0) 1 4 (19.0) 4 (16.7)
Anemia  0 0 (0.0) 0 3 (14.3) 3 (12.5)
Hypertriglyceridemia 0 1 (33.3) 0 2 (9.5) 3 (12.5)
Headache 0 0 (0.0) 0 3 (14.3) 3 (12.5)
Dry  eye 0 1 (33.3) 0 2 (9.5) 3 (12.5)
Cough  0 1 (33.3) 0 2 (9.5) 3 (12.5)
Abdominal pain upper 0 1 (33.3) 0 2 (9.5) 3 (12.5)
Constipation 0 1 (33.3) 0 2 (9.5) 3 (12.5)
Proteinuria 0 0 (0.0) 0 3 (14.3) 3 (12.5)
Blood  alkaline phosphatase increased 0 0 (0.0) 0 3 (14.3) 3 (12.5)
Blood  uric acid decreased 0 0 (0.0) 0 3 (14.3) 3 (12.5)
Table 3
Pharmacokinetic parameters after intravenous infusion of patritumab.
Parameters Unit Patritumab 9 mg/kg
(N = 3) mean ± SD
Patritumab 18 mg/kg
(N = 11) mean ± SD
AUC0-21day g day/mL 1190 ± 87.6 2480 ± 420
Cmax g/mL 242 ± 29.4 400 ± 46.7
CL  mL/day/kg 6.94 ± 0.72 6.61 ± 1.08
Vss mL/kg 51.4 ± 2.97 58.0 ± 14.8
T1/2 day 6.44 ± 1.20 7.12 ± 2.30
AUC, area under the curve; Cmax, maximum concentration; CL, total body clearance; Vss, apparent volume of distribution at steady state; T1/2; half-life.
Fig. 1. Cmax and AUC for patritumab in Phase I studies in Japan and the US. NSCLC: non-small cell lung cancer.
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Fig. 2. Kaplan–Meier analysis of progression-free survival: subgroup analysis by EGFR status. EGFR: epidermal growth factor receptor.
Table 4
HER3 levels in tumor samples, EGFR status and tumor responses in NSCLC patients.
HER3 expression (IHC: membrane) Total N = 11 EGFR status Best response
Mutant Wild-type PR SD PD
N  = 7 N = 4 N = 1 N = 5 N = 5
3+ 0 0 0 0 0 0
2+  6 5 1 1 3 2
1+  1 1 0 0 1 0
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HC, immunohistochemistry; EGFR, epidermal growth factor receptor; NSCLC, non-
max values were 242 and 400 g/mL; and the terminal half-lives
ere 6.44 and 7.12 days, respectively. The AUC and Cmax values for
atritumab are shown in Fig. 1. The AUC and Cmax values in this
tudy were within a similar range to those from phase I studies in
apan and the US (Fig. 1) [18,19].
.4. Efﬁcacy
One partial response (PR) and 14 cases with stable disease (SD)
1 SD at level 1, and 1 PR and 13 SD at level 2) were observed at
 weeks. The overall response rate (ORR) was 4.2% and the disease
ontrol rate (DCR = CR + PR + SD) was 62.5%.
The PR was observed in a patient who had a tumor with an
GFR-activating mutation (L858R) but who had received no prior
GFR-TKI. Among the 14 SD patients, 10 patients had tumors with
n EGFR-activating mutation and received prior geﬁtinib treatment
exon 19 del, n = 5; L858R, n = 4; exon 18 and 21 del, n = 1), 3 patients
ad a tumor with wild-type EGFR and 1 patient had a tumor with an
nknown EGFR status without a history of prior geﬁtinib treatment.
The progression-free survival (PFS) is shown in Fig. 2. The
edian PFS (95% conﬁdence interval) was 44.0 (22.0–133.0) days
or the EGFR wild-type group (n = 9) and 107.0 (74.0–224.0) days for
he EGFR-activating mutation group (n = 13). The median PFS (95%
onﬁdence interval) in patients who had a tumor with an EGFR-
ctivating mutation and who had received prior geﬁtinib treatment
n = 12) was 107.0 (74.0–224.0) days.
.5. Biomarker analysisTumor tissues for biomarker identiﬁcation analysis were
btained from 11 patients. HER3 protein levels, EGFR mutation
tatus, and tumor responses of these patients are summarized3 0 1 3
cell lung cancer; PR, partial response; SD, stable disease; PD, progressive disease.
in Table 4. A correlation between tumor response and HER3
expression was not found. Serum soluble HER3 concentrations
during treatment with patritumab and erlotinib signiﬁcantly
increased from baseline in all patients. Soluble HER3 con-
centrations (mean ± SD) at baseline were 6.88 ± 0.48 ng/mL for
9 mg/kg (n = 3) and 7.35 ± 2.48 ng/mL for 18 mg/kg (n = 21) groups.
Soluble HER3 concentrations (mean ± SD) on cycle 1 day 21
were 29.72 ± 1.14 ng/mL for the 9 mg/kg (n = 3) group and
27.53 ± 6.17 ng/mL for the 18 mg/kg (n = 21) group. There was no
statistically signiﬁcant difference in soluble HER3 concentrations
between dose groups. A correlation between serum soluble HER3
concentrations during the treatment and tumor response was not
found.
4. Discussion
We completed the ﬁrst phase I study of patritumab in combina-
tion with erlotinib that evaluated the safety, pharmacokinetics and
potential biomarkers in patients with previously treated advanced
NSCLC. We  found that the combination therapy had good efﬁcacy
in advanced NSCLC patients, especially for those who had tumors
with EGFR-activating mutations and had developed resistance to
geﬁtinib treatment.
The ﬁndings in the current study (the median PFS of patients
with EGFR-activating mutations who  received prior geﬁtinib treat-
ment (n = 12) was  3.56 months, and there were 13 patients (92.9%)
with SD at level 2) compared favorably to the ﬁndings of recent
studies investigating third-generation EGFR-TKIs. Early phase I
results with CO-1686, a third-generation EGFR-TKI, indicated that,
of 9 patients with EGFR-activating mutations and failed EGFR-TKI
therapy, 2 (22.2%) had SD [23]. A study investigating another third-
generation EGFR-TKI, AZD9291, demonstrated that 15 patients
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43%) had conﬁrmed or unconﬁrmed PR [24]. A phase Ib study of
atients with EGFR-TKI resistance treated with combined afatinib
nd cetuximab showed that 35% of patients responded and 95%
ad SD [25], demonstrating a better response than was  shown in a
rial using afatinib alone (response rate of 8.2%, median PFS of 4.4
onths with a median overall survival of 19.0 months) [26].
A study investigating the use of cetuximab in EGFR-positive
SCLC demonstrated a small beneﬁt when it was  used in com-
ination with chemotherapy (median OS of 11.3) compared with
hemotherapy alone (10.1 months, P = 0.044) [27]. However, the
edian PFS was 4.8 months in both groups.
The most common AEs in this study were gastrointestinal and
kin toxicities, which were generally mild and manageable. No
eaths due to adverse events were reported. Some SAEs were
eported including grade 2 cancer pain, which was  attributable
o the primary disease and was unrelated to either patritumab or
rlotinib treatment. No DLTs were reported at either dosage levels
patritumab 9 or 18 mg/kg with oral daily dose of erlotinib 150 mg)
nd the doses tested did not reach MTD. Although most AEs in this
tudy were similar to the well-known side effects of erlotinib, patri-
umab might have caused an incremental increase in the incidence
f diarrhea compared with the incidence in a previous Japanese
hase II study of erlotinib alone (95.8% vs. 74%) [28]. The incidence
nd rates of other grade 3 or 4 AEs including skin toxicities were
imilar to those in a previous erlotinib study [29]. Therefore, patri-
umab at a dose of 18 mg/kg in combination with an oral daily dose
f erlotinib 150 mg  was determined as the recommended dose for
uture studies in Japanese patients with NSCLC. The levels of phar-
acokinetic parameters or patritumab in this study were similar
o those observed in previous phase I studies of patritumab [18,19].
urthermore, no neutralizing antibodies were detected in patients
n this study after patritumab administration, as assessed by an
nti-patritumab antibody and cell-based bioassay, similar to ﬁnd-
ngs in previous studies [18,19].
In terms of efﬁcacy of the combined treatment, 1 PR and 14 cases
ith SD were observed. The ORR was 4.2% and the DCR was 62.5%.
he PR patient had a tumor with an EGFR-activating mutation and
id not receive prior geﬁtinib treatment. The low ORR might be
xplained by the patient characteristics including the presence of
ild-type EGFR and prior geﬁtinib treatment.
For the exploratory analysis, we separately evaluated the efﬁ-
acy of this combination in patients with wild-type EGFR and those
ith EGFR mutations who developed resistance to geﬁtinib treat-
ent. Of 9 patients with wild-type EGFR, 3 had SD (DCR 33%) and
he median PFS for all 9 patients was 44.0 days. These results were
ot encouraging because they were similar to those obtained with
he use of erlotinib alone in recent phase III studies in patients
ith previously treated NSCLC and wild-type EGFR (DCR 26% with
 median PFS of 2.4 months [30], and DCR 52.8% with a median PFS
f 1.3 months [31]). However, 10 SDs were observed in 12 patients
ith EGFR mutations who received prior geﬁtinib treatment. In the
urrent study, the cohort DCR was 83.3% and the median PFS was
07 days. Although the results were limited because of the small
umber of patients, the DCR and median PFS are encouraging and
uggest that patritumab might enhance the activity of erlotinib in
atients with EGFR-activating mutations who develop resistance to
eﬁtinib treatment, because the DCR and median PFS in a previous
hase II study of erlotinib alone in patients after failure of geﬁtinib
ere only 28.6% and 60 days, respectively [32].
With respect to biomarkers, we investigated the correlation
etween HER3 expression in tumor tissues and the efﬁcacy of
ombined patritumab and erlotinib treatment. Although recent
tudies suggested that HER3 was involved in the resistance to other
ER receptor-targeted therapies [12], we observed no correlation
etween tumor response and HER3 expression in tumor tissues or
erum soluble HER3 levels before treatment. An explanation for the
[
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lack of correlation between HER3 and efﬁcacy might be the type
of tumor tissues used in this study or the relatively low numbers
of patients studied. Because we tested HER3 expression from tis-
sue archived at the initial diagnosis, we  could not examine HER3
expression just prior to this study. To conﬁrm that hypothesis, it
would be necessary to examine these biomarkers in larger numbers
of patients in future studies.
In addition, serum soluble HER3 levels were signiﬁcantly
increased in all patients during treatment and serum soluble
biomarkers were similar to those observed in previous studies of
patritumab [19]. The mechanisms underlying these phenomena are
unclear and require further study.
In conclusion, patritumab in combination with erlotinib was
well tolerated up to 18 mg/kg without DLTs in previously treated
Japanese NSCLC patients. This preliminary demonstration of the
efﬁcacy of the combined treatment was  encouraging, especially in
NSCLC patients with EGFR-activating mutations where prior geﬁt-
inib treatment failed.
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